 |
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
The clinical study was conducted in Australiafr...
“The Federal Budget delivered several measures aimed at supporting small businesses, including making the instant asset write-off permanent, exten...
Cooee Native Superfoods’ Bunji range of dog kibble and treats is rolling out across Ritchies Supermarkets now, with stock already on shelves in se...
“Australian corporates and SMBs are under pressure. Competition from global players is intensifying, margins are under strain, and technology adop...
Superannuation fund Brighter Super is encouraging business owners to prepare now for Payday Super, ahead of the new laws taking effect from 1 July...
PayNuts, one of Australia’s fastest-growing payment service providers, has unveiled a refreshed brand identity and an expanded suite of integrated b...
Australian small business owners can now receive and compare business insurance quotes directly inside ChatGPT, in a move that signals a major shi...